---
title: "Atea Pharmaceuticals | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286153339.md"
datetime: "2026-05-12T20:31:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286153339.md)
  - [en](https://longbridge.com/en/news/286153339.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286153339.md)
---

# Atea Pharmaceuticals | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.57, beating the estimate of USD -0.59.

EBIT: As of FY2026 Q1, the actual value is USD -50.63 M.

#### Cash, Cash Equivalents and Marketable Securities

As of March 31, 2026, cash, cash equivalents and marketable securities were $256.0 million, a decrease from $301.8 million at December 31, 2025 .

#### Research and Development Expenses

Research and development expenses increased to $41.1 million for the three months ended March 31, 2026, from $29.6 million for the same period in 2025, representing an increase of $11.6 million . This increase was partially due to higher external spend for the HCV Phase 3 clinical development and HEV preclinical development .

#### General and Administrative Expenses

General and administrative expenses decreased by $2.6 million to $6.9 million for the three months ended March 31, 2026, compared to $9.5 million for the three months ended March 31, 2025 . This decrease was primarily related to lower salaries and wages, stock-based compensation, and professional fees .

#### Interest Income and Other, Net

Interest income and other, net, decreased by $2.4 million for the three months ended March 31, 2026, compared to the same period in 2025, primarily due to lower investment balances . For the three months ended March 31, 2026, it was $2.618 million, down from $4.972 million in the prior year period .

#### Income Tax Expense

Income tax expense was -$0.050 million for the three months ended March 31, 2026, compared to -$0.203 million for the three months ended March 31, 2025 .

#### Net Loss

The net loss for the three months ended March 31, 2026, was -$45.440 million, compared to a net loss of -$34.272 million for the three months ended March 31, 2025 .

#### Loss from Operations

Loss from operations was -$48.008 million for the three months ended March 31, 2026, compared to -$39.041 million for the three months ended March 31, 2025 .

#### Total Operating Expenses

Total operating expenses were $48.008 million for the three months ended March 31, 2026, up from $39.041 million for the three months ended March 31, 2025 .

#### Comprehensive Loss

Comprehensive loss was -$45.711 million for the three months ended March 31, 2026, compared to -$34.387 million for the three months ended March 31, 2025 .

#### Working Capital

Working capital was $229.830 million at March 31, 2026, decreasing from $271.207 million at December 31, 2025 .

#### Total Assets

Total assets were $267.076 million at March 31, 2026, down from $315.218 million at December 31, 2025 .

#### Total Liabilities

Total liabilities were $33.367 million at March 31, 2026, compared to $39.784 million at December 31, 2025 .

#### Total Stockholder’s Equity

Total stockholder’s equity was $233.709 million at March 31, 2026, a decrease from $275.434 million at December 31, 2025 .

#### Outlook / Guidance

Atea Pharmaceuticals, Inc. anticipates topline results for its C-BEYOND Phase 3 North American trial for Hepatitis C Virus (HCV) treatment by mid-2026 . The C-FORWARD Phase 3 trial outside North America is expected to complete enrollment by mid-2026, with topline results projected around year-end 2026 . Furthermore, the company plans to initiate a Phase 1 clinical program for AT-587, a potential first-in-class candidate for Hepatitis E Virus (HEV), in mid-2026 .

### Related Stocks

- [AVIR.US](https://longbridge.com/en/quote/AVIR.US.md)

## Related News & Research

- [Insights Ahead: Atea Pharmaceuticals's Quarterly Earnings](https://longbridge.com/en/news/277813759.md)
- [Atea Increases Treasury Share Holdings Under Ongoing Buyback Program](https://longbridge.com/en/news/280839230.md)
- [Atea Pharmaceuticals (NASDAQ:AVIR) Trading Down 1.9%  - Should You Sell?](https://longbridge.com/en/news/269332477.md)
- [JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens](https://longbridge.com/en/news/272991785.md)